Type 2 diabetes does not only affect blood sugar. Over time, persistently high glucose levels can quietly damage the kidneys, a complication called diabetic nephropathy. Once kidney function starts declining, the health system costs climb steeply and patient quality of life drops. Researchers and policymakers therefore want to know not just whether a medication helps the kidneys, but whether the benefit is worth the added expense.
A study published in the journal Cost Effectiveness and Resource Allocation tackled exactly that question for the German public health system. Using a computer-based simulation, the research team compared three second-line glucose-lowering medications added on top of standard care, estimating how each one affected kidney disease progression, life expectancy, quality-adjusted survival, and direct medical costs over a patient's lifetime.
The peptide-based agent examined in the study, a GLP-1 receptor agonist that works by mimicking a gut hormone to regulate blood sugar, sat in the middle of the pack on cost-effectiveness. Understanding what the model found, and what its limits are, matters for anyone following the science around metabolic health and kidney disease.
The simulation design
The research team built what is called a Markov microsimulation model. Think of it as a digital patient who moves through different stages of kidney health over time, from normal function all the way to kidney failure, with the model tracking costs and quality of life at each step. The model pulled transition probabilities, meaning the odds of moving from one kidney stage to the next, along with cost and quality-of-life estimates, from previously published medical literature.
The primary patient cohort started at age 62.8 years, which reflects a realistic average age for people diagnosed with type 2 diabetes in Germany. A secondary scenario was also run starting at age 50 to test whether findings held for younger patients. Future costs and health outcomes were discounted at three percent per year, a standard economic convention that accounts for the fact that money and health in the near future are worth more than the same values far in the future.
The willingness-to-pay threshold, the ceiling the German statutory health system was assumed to accept for one additional quality-adjusted life year, was set at 100,000 euros. Interventions falling below that ceiling per quality-adjusted life year gained are generally considered cost-effective in this framework.
What quality-adjusted life years showed
A quality-adjusted life year, often abbreviated QALY, combines how long a person lives with how healthy they feel during that time. A year in perfect health equals one QALY; a year with serious illness counts for less. The model found that standard care alone produced 10.28 quality-adjusted life years for the simulated patient cohort.
Adding empagliflozin, a drug from the SGLT-2 inhibitor class, raised that figure to 10.48 QALYs. Adding the GLP-1 receptor agonist examined in the study pushed it further to 10.58 QALYs. The dual-action agent tirzepatide, which targets two different hormone receptors simultaneously, reached 10.75 QALYs. Each step up represented meaningful additional healthy time in the model, even if the differences look small in raw numbers.
Life expectancy and direct costs
Life expectancy followed a similar pattern. Standard care projected 13.36 years of remaining life from the starting age. The three medications extended that to 13.66, 13.76, and 14.00 years respectively, with the dual-action agent producing the longest projected survival.
Direct costs told a very different story. Standard care totaled about 66,344 euros in lifetime medical costs. Adding the SGLT-2 inhibitor brought total costs to roughly 79,767 euros. Adding the GLP-1 receptor agonist reached approximately 84,329 euros. Adding the dual-action agent pushed costs dramatically higher to about 155,993 euros, more than double the standard care baseline. That steep cost increase is driven largely by the higher price of the dual-action medication itself.
The net monetary benefit calculation, which weights the QALY gains against costs at the chosen threshold, showed the GLP-1 receptor agonist and the SGLT-2 inhibitor both producing higher net monetary benefit than standard care alone. The dual-action agent, despite the best clinical outcomes, fell below standard care on this measure because its costs were so much higher relative to its incremental health gains.
Cost-effectiveness conclusions from the model
At the 100,000 euros per QALY threshold, both the SGLT-2 inhibitor and the GLP-1 receptor agonist remained cost-effective across all scenarios the researchers tested, including the younger starting age of 50. The dual-action agent did not clear that bar, primarily because its drug costs were so high that the extra health benefit did not offset the expense within the chosen framework.
The researchers ran multiple one-way sensitivity analyses, meaning they changed one input at a time to see how much the results shifted. The two factors that had the greatest influence on cost-effectiveness findings were the quality-of-life weight assigned to living with type 2 diabetes and the cost of the intervention itself. Neither patient age nor sex materially changed the conclusions, which gives the findings some robustness across different patient profiles.
Context and study limits
Any model-based study carries inherent limitations. The transition probabilities and utility values feeding the simulation came from existing published literature rather than a new clinical trial, so the model is only as good as the data it was built on. Real-world patients differ in ways a simulation cannot fully capture, including adherence to medication, other diseases they may have, and individual kidney-disease trajectories.
The study looked exclusively at kidney outcomes and did not model cardiovascular or other benefits that some of these agents have shown in separate clinical research. If those additional benefits were included, the cost-effectiveness picture for some agents might look different. The analysis also reflects German healthcare pricing, so the numbers would not translate directly to other health systems with different drug prices or different willingness-to-pay thresholds.
Still, the study is notable for providing a rare kidney-specific, head-to-head economic comparison of multiple agents within a single model, addressing a gap the authors themselves identified in the German health-economics literature.
Broader relevance for metabolic peptide research
The GLP-1 receptor agonist class, which includes peptide-based compounds that mimic the gut hormone glucagon-like peptide 1, has attracted intense research interest well beyond blood sugar control. A growing body of literature suggests these agents may have protective effects on multiple organ systems, including the kidneys, through mechanisms that researchers are still working to fully characterize.
The modeling study adds an economic dimension to that scientific picture. It suggests that even when a GLP-1 receptor agonist costs more than standard care, the kidney-related health gains it produces may justify that additional spend within a specific policy framework. For researchers studying metabolic peptides more broadly, findings like these highlight how the downstream consequences of organ protection can shift the health-economics calculus in meaningful ways.
